IP Library Granted Patent US 12,305,170
Granted Patent B1
US 12,305,170 · App. 18/518,014 · Granted May 20, 2025

Composition for regulating production of interfering ribonucleic acid

Inventor: Bradley G. Thompson (Calgary, CA)
Assignee: Wyvern Pharmaceuticals Inc.
C12N15/1137C12N15/113C12N15/86C12Y114/16002C12N2310/141C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,305,170
App. No.
18/518,014
Granted
May 20, 2025
Kind
B1
Abstract

The embodiments of the present disclosure relate to decreasing the bioavailability of one or more target biomolecules by providing a composition that comprises a recombinant plasmid with one or more sequences of micro interfering ribonucleic acid (miRNA). When the recombinant plasmid interacts with a target cell, it causes the target cell to upregulate production of the miRNA, which then decreases the bioavailability of the target biomolecule. In some embodiments of the present disclosure, the target biomolecule is a protein that participates in one or more intracellular processes.

Claims (6)

1. A composition that comprises a recombinant plasmid (RP) with a sequence of nucleotides according to SEQ ID NO: 1 that comprise a start region, an end region and an insert positioned between the start region and the end region, in which the insert encodes for an insert sequence of micro interfering ribonucleic acid (miRNA) that binds to and causes degradation of messenger ribonucleic acid (mRNA) that encodes for a target biomolecule, wherein the target biomolecule participated in one or more intra-cellular processes, wherein the insert sequence comprises 95-100% of a same nucleotide sequence as one of SEQ ID NO: 2, SEQ ID NO: 3; and SEQ ID NO: 4.

2. The composition of claim 1 , wherein the sequence of nucleotides is configured to be delivered to a target cell that has an over-expressed or mis-expressed biomolecule, wherein the sequence of nucleotides is encased in a protein coat, a lipid vesicle, or any combination thereof.

3. The composition of claim 1 wherein: when the insert sequence comprises 95-100% of the same nucleotide sequence as SEQ ID NO: 2 the target molecule is MRS2, when the insert sequence comprises 95-100% of the same nucleotide sequence as SEQ ID NO: 3 the target molecule is DUX4, and when the insert sequence comprises 95-100% of the same nucleotide sequence as SEQ ID NO: 4, the target molecule is tyrosine hydroxylase.

4. The composition of claim 1 , wherein the sequence of nucleotides is configured to be delivered to a target cell that has an over-expressed or mis-expressed biomolecule, wherein the sequence of nucleotides is encased in a virus vector.

5. The composition of claim 4 , wherein the virus vector is one of a double stranded DNA virus, a single stranded DNA virus, a single stranded RNA virus, or a double stranded RNA virus.

6. The compositions of claim 4 , wherein the virus vector is an adeno-associated virus.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2025
From: THOMPSON, BRADLEY G.
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 071987/0576 →
References Cited (3)
US 20140322169A1 · Harper · 2014 [cited by examiner]
O'Brien at al., “Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation”, Frontiers in Endocrinology, vol. 9, Published Aug. 3, 2018, pp. 1-9. (Year: 2018). [cited by examiner]
Zhang et al., “The Risks of miRNA Therapeutics: In a Drug Target Perspective”, Drug Design, Development and Therapy, Published Feb. 22, 2021, pp. 721-733. (Year: 2021). [cited by examiner]